BeiGene Proudly Sponsors

Chinese American Hematologists and Oncologists Network (CAHON)

New York Oncology Forum

2020 Virtual Series

Website: www.beigene.com
Twitter: @BeiGeneUSA
LinkedIn: www.linkedin.com/company/BeiGene

BeiGene

The BeiGene Story

A global biotechnology innovator focused on improving treatment outcomes and patient access

BeiGene is a fully-integrated biotechnology company co-founded in 2010 by John Oyler, an American entrepreneur, and Dr. Xiaodong Wang, one of the youngest ever U.S. Academy of Science members and Director of China's National Institute of Biological Sciences (NIBS) in Beijing. The two set out to build a unique company that was globally focused from its inception.

BeiGene (NASDAQ: BGNE; HKEX 06160) focuses on developing novel therapies where there is global unmet need.

4,200+
employees
(as of August 6, 2020)

10 offices
on 4 continents

Trials in 35
countries and regions



Our broad product portfolio and pipeline include:

- 3 wholly owned late-stage oncology candidates, including one approval in the U.S. and four approvals in China
- 27 Phase 3 or potentially registration-enabling trials ongoing, 60+ studies in total
- 32 clinical or commercial stage assets including seven internally developed and 25 in-licensed

BeiGene has built a strong innovative pipeline of clinical drug candidates through internal discovery and collaborations.

BeiGene

Tislelizumab Broad Late-stage Development Program

Sixteen filed or potentially registration-enabling studies



^Time of the announcement of the enrollment completion; *Tislelizumab dosage 200mg every three weeks, Q3W. Global Ph2 in R/R/ NK/T-cell lymphoma and Ph2 trial in MSI-H or dMMR solid tumors in China are potentially registrational-enabling trials. 1/2L: First/Second Line; cCRT: concurrent chemoradiotherapy; cHL: Classical Hodgkin's Lymphoma; ESCC: Esophageal Squamous-Cell Carcinoma; GC: Gastric Cancer; HCC: Hepatocellular Carcinoma; IRC: Independent Review Committee; ITT: Intent-to-treat; MSI-H or dMMR: Microsatellite Instability High or Deficient Mismatch Repair; NDA: New Drug Application; NK: Natural Killer; NSCLC: Non-Small Cell Lung Cancer; ORR: Overall response rate; OS: Overall survival; PE: Primary Endpoint; PFS: Progression-free survival; R/R: Relapsed / Refractory; UC: Urothelial Carcinoma;

BeiGene